Newsroom | 5144 results

BOSTON--(BUSINESS WIRE)--Elucid today announced that, effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. Together, these developments underscore the clinical value of coronary plaque analysis and establish favorable conditions for broader adoption of the technology. Quantitative coronary plaque analysis...

ST. LOUIS--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE: RGA) plans to release fourth quarter earnings on Thursday, February 5, at approximately 4:15 p.m. Eastern Time. The release will be issued via newswire and will also be available through RGA’s website, www.rgare.com. RGA will host a conference call to discuss the fourth quarter results beginning at 10 a.m. Eastern Time on Friday, February 6. Interested parties may access the call by dialing 1-844-481-2753 (412-317-066...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of RxSmartSaver powered by GoodRx at Giant Eagle pharmacies, giving patients a fast and easy way to access lower prices on high-cost brand medications directly at the pharmacy counter. “We are excited to partner with Giant Eagle to make brand medications more affordable and easier to access for the many patients who rely on them,” said David Graziano,...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and their families through TRICARE, the U.S. military’s health insurance coverage, with no copay for average-risk individuals ages 45 and older. Shield is the first and only blood test approved by the FDA as a primary screening option for CRC, offering U.S. military...

PHILADELPHIA--(BUSINESS WIRE)--Lyric, a leader in payment integrity AI and claims analytics for health plans, today announced the appointment of Halsey Wise as CEO...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported certain unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter Strategic and Operational Highlights Secured Milestone Medicare Coverage: Received Medicare coverage approval for the surveillance of cancer recurrence in breast cancer patients, a key catalyst for clinical revenue and mar...

DUBAI, United Arab Emirates--(BUSINESS WIRE)--Pacific Prime Dubai, a global health insurance broker, risk specialist, and benefits specialist, concluded the year 2025 strongly with the AXA Global Healthcare/Daman Market Excellence Award. The award was presented by Karim Idilby, Chief Growth Officer of AXA/Daman, at the Pacific Prime Dubai office on 10 December 2025, with Pierre de Mirman, Global Managing Director; Michael Lavelle, Head of Individual Sales; Mark McClelland, Director of Commercia...

SHELTON, Conn.--(BUSINESS WIRE)--As employers and unions nationwide struggle with pharmacy costs that can consume as much as 40% of healthcare budgets, PBIRx, an independent adviser that audits pharmacy benefit managers (PBMs) and has recovered over $500 million for clients, is tripling its office space and expanding staff by 50% to meet rising demand. The consulting firm has grown by 25% annually for three years as more employers and unions seek greater transparency, accountability, and a clea...

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Announces 2025 Performance Analysis of Patient Affordability Solutions...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen. “We have taken learnings from Johnson & Johnson’s 140 years in surge...